CDK19 x FLT3 x c-Met x NTRK x AXL x CDK8

主要研究目的：评估TSN084片在晚期或转移性恶性肿瘤受试者中的安全性、耐受性、剂量限制性毒性（DLTs）和初步抗肿瘤活性，确定最大耐受剂量（MTD）、扩展期推荐剂量（RDE）和II期临床研究推荐剂量。次要研究目的：评估TSN084片药代动力学（PK）特征和初步抗肿瘤活性。探索性研究目的：探索TSN084的暴露量/剂量与安全性以及临床疗效之间的关系以及生物标志物。

TSN084 is a novel type II kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This phase 1a/1b study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies in China.

TSN084 is a novel type II protein kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies.